<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01595672</url>
  </required_header>
  <id_info>
    <org_study_id>SAP-CVVH-XHDD-002</org_study_id>
    <secondary_id>81170432</secondary_id>
    <nct_id>NCT01595672</nct_id>
  </id_info>
  <brief_title>Early High-volume Continuous Veno-venous Hemofiltration for Patients With Severe Acute Pancreatitis</brief_title>
  <acronym>EHVCVVHSAP</acronym>
  <official_title>Early High-volume Continuous Veno-venous Hemofiltration for Patients With Severe Acute Pancreatitis: Single-center, Randomized, Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fourth Military Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fourth Military Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect and safety of early high-volume
      continuous veno-venous hemofiltration for patients with severe acute pancreatitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators anticipated that early high-volume continuous veno-venous hemofiltration
      (EHVCVVH) would result in a decrease of the composite of persistent organ failure or death by
      eliminating inflammatory mediators in blood. This study is designed to evaluate the impact of
      EHVCVVH on patients with severe acute pancreatitis.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2012</start_date>
  <completion_date type="Anticipated">March 2013</completion_date>
  <primary_completion_date type="Anticipated">February 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>persistent organ failure or death</measure>
    <time_frame>1 months</time_frame>
    <description>persistent organ failure: organ failure ≥ 48 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>death</measure>
    <time_frame>1 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>persistent organ failure</measure>
    <time_frame>1 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>infectious complications</measure>
    <time_frame>1 months</time_frame>
    <description>infected necrosis,bacteraemia and pneumonia respectively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>input fluid volume within first 3 days after admission</measure>
    <time_frame>3 days</time_frame>
    <description>crystalloid fluids and colloid fluids respectively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physiological Parameters 1 day, 2 days, and 3 days after randomization</measure>
    <time_frame>3 days</time_frame>
    <description>Physiological Parameters: APACHE-II score,SOFA score,Body temperature,PaO2/FiO2,BE,PLT,Cr,serum Ca,WBC and Urine volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The concentration of inflammatory mediators in serum 0 hour,2 hours,6 hours and 12 hours after early high-volume continuous veno-venous hemofiltration</measure>
    <time_frame>12 hours</time_frame>
    <description>inflammatory mediators: tumor necrosis factor-α, IL-1, IL-2, IL-4, IL-6, and IL-8, IL-10, IL-13, IL-15, Angiopoietin-2, trypsin, resistin and visfatin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total number of surgical interventions</measure>
    <time_frame>2 months</time_frame>
    <description>for any purpose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU stay</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total costs in hospital</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>output fluid volume in the first, second, third day after admission</measure>
    <time_frame>3 days</time_frame>
    <description>output: urine volume,ultrafiltration liquids,gastric drainage and defecation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>persistent multiple organ dysfunction syndrome</measure>
    <time_frame>1 months</time_frame>
    <description>multiple organ dysfunction syndrome (two or more organs or occurrence of two or more systemic complications at the same time) ≥ 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>new-onset organ failure</measure>
    <time_frame>1 months</time_frame>
    <description>not present at any time in the 24 hours before randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>new-onset multiple organ dysfunction syndrome</measure>
    <time_frame>1 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Acute Pancreatitis</condition>
  <arm_group>
    <arm_group_label>EHVCVVH group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive conventional treatments recommended by guidelines with adjunctive early high-volume continuous veno-venous hemofiltration (EHVCVVH).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive conventional treatments recommended by guidelines only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AN69 hemofilter</intervention_name>
    <description>An AN69 hemofilter (1.6 m2 surface area, 35-KD limit; Baxter Healthcare Corp. Deerfield, IL, USA) will be used for EHCVVH.</description>
    <arm_group_label>EHVCVVH group</arm_group_label>
    <other_name>high-volume hemofiltration</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>conventional treatments</intervention_name>
    <description>Patients receive conventional treatments recommended by guidelines only.</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>standard treatments</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  clinical diagnosis of severe acute pancreatitis

          -  written informed consent

          -  Time from onset of abdominal pain to admission ≤ 72 hours

          -  SIRS score ≥ 2

        Exclusion Criteria:

          -  confirmed infection

          -  pregnancy

          -  patients needing emergency operation for abdominal compartment syndrome

          -  chronic renal diseases needing blood purification

          -  previous exploratory laparotomy for acute abdomen and diagnosis of pancreatitis during
             laparotomy

          -  acute flare-up of chronic pancreatitis

          -  malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhao Qingchuan, PhD &amp; MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>the First Affiliated Hospital of Fourth Military Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhao Qingchuan, PhD &amp; MD</last_name>
    <phone>86-29-84771503</phone>
    <email>zhaoqc@fmmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhang Xujie, MD</last_name>
    <phone>86-13991230324</phone>
    <email>602914766@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Xijing Hospital of Digestive Diseases</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhao Qingchuan, PhD &amp; MD</last_name>
      <phone>86-29-84771503</phone>
      <email>zhaoqc@fmmu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Zhang Xujie, MD</last_name>
      <phone>86-13991230324</phone>
      <email>602914766@qq.com</email>
    </contact_backup>
    <investigator>
      <last_name>Zhao Qingchuan, PhD &amp; MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhang Xujie, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2012</study_first_submitted>
  <study_first_submitted_qc>May 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2012</study_first_posted>
  <last_update_submitted>May 8, 2012</last_update_submitted>
  <last_update_submitted_qc>May 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fourth Military Medical University</investigator_affiliation>
    <investigator_full_name>Qingchuan Zhao</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>severe acute pancreatitis</keyword>
  <keyword>organ failure</keyword>
  <keyword>multiple organ dysfunction syndrome</keyword>
  <keyword>systemic complications</keyword>
  <keyword>continuous veno-venous hemofiltration</keyword>
  <keyword>blood purification</keyword>
  <keyword>continuous renal replacement therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

